Page 94 - GPD-2-2

Gene & Protein in Disease Verteporfin therapy for triple-negative breast cancer

19. Al-Moujahed A, Brodowska K, Stryjewski TP, et al., 2017, of YAP-TEAD complex, presents promising antitumor
Verteporfin inhibits growth of human glioma in vitro properties on ovarian cancer. Onco Targets Ther,
without light activation. Sci Rep, 7(1): 7602. 9: 5371–5381.
https://doi.org/10.1038/s41598-017-07632-8 https://doi.org/10.2147/OTT.S109979
20. Ma YW, Liu YZ, Pan JX, 2016, Verteporfin induces apoptosis 28. Huang Y, Ahmad US, Rehman A, et al., 2022, YAP inhibition
and eliminates cancer stem-like cells in uveal melanoma by verteporfin causes downregulation of desmosomal genes
in the absence of light activation. Am J Cancer Res, 6(12): and proteins leading to the disintegration of intercellular
2816–2830. junctions. Life (Basel), 12(6): 792.
21. Gibault F, Bailly F, Corvaisier M, et al., 2017, Molecular https://doi.org/10.3390/life12060792
features of the YAP inhibitor verteporfin: Synthesis of 29. Musgrove EA, Lee CS, Buckley MF, et al., 1994, Cyclin D1
hexasubstituted dipyrrins as potential inhibitors of YAP/ induction in breast cancer cells shortens G1 and is sufficient
TAZ, the downstream effectors of the Hippo pathway. for cells arrested in G1 to complete the cell cycle. Proc Natl
ChemMedChem, 12(12): 954–961.
Acad Sci U S A, 91(17): 8022–8026.
https://doi.org/10.1002/cmdc.201700063
https://doi.org/10.1073/pnas.91.17.8022
22. Pan W, Wang Q, Zhang Y, et al., 2016, Verteporfin can reverse 30. Toyoshima H, Hunter T, 1994, P27, a novel inhibitor of G1
the paclitaxel resistance induced by YAP over-expression in cyclin-Cdk protein kinase activity, is related to p21. Cell,
HCT-8/T cells without photoactivation through inhibiting 78(1): 67–74.
YAP expression. Cell Physiol Biochem, 39(2): 481–490.
https://doi.org/10.1016/0092-8674(94)90573-8
https://doi.org/10.1159/000445640
31. Askew D, Ashmun RA, Simmons BC, et al., 1991,
23. Wang C, Zhu X, Feng W, et al., 2016, Verteporfin inhibits Constitutive c-myc expression in an IL-3-dependent
YAP function through up-regulating 14-3-3σ sequestering myeloid cell line suppresses cell cycle arrest and accelerates
YAP in the cytoplasm. Am J Cancer Res, 6(1): 27–37.
apoptosis. Oncogene, 6(10): 1915–1922.
24. Brodowska K, Al-Moujahed A, Marmalidou A, et al., 2014, 32. Nishimoto M, Uranishi K, Asaka MN, et al., 2019,
The clinically used photosensitizer Verteporfin (VP) inhibits Transformation of normal cells by aberrant activation of
YAP-TEAD and human retinoblastoma cell growth in vitro YAP via cMyc with TEAD. Sci Rep, 9(1): 10933.
without light activation. Exp Eye Res, 124: 67–73.
https://doi.org/10.1038/s41598-019-47301-6
https://doi.org/10.1016/j.exer.2014.04.011
33. Huang J, Wu S, Barrera J, et al., 2005, The Hippo signaling
25. Wei C, Li X, 2020, Verteporfin inhibits cell proliferation and pathway coordinately regulates cell proliferation and
induces apoptosis in different subtypes of breast cancer cell apoptosis by inactivating Yorkie, the Drosophila Homolog of
lines without light activation. BMC Cancer, 20: 1042.
YAP. Cell, 122(3): 421–434.
https://doi.org/10.1186/s12885-020-07555-0
https://doi.org/10.1016/j.cell.2005.06.007
26. Wei C, Li X, 2020, Determination of the migration effect 34. Andrade D, Mehta M, Griffith J, et al., 2017, YAP1 inhibition
and molecular docking of verteporfin in different subtypes radiosensitizes triple negative breast cancer cells by targeting
of breast cancer cells. Mol Med Rep, 22(5): 3955–3961.
the DNA damage response and cell survival pathways.
https://doi.org/10.3892/mmr.2020.11482 Oncotarget, 8(58): 98495–98508.
27. Feng J, Gou J, Jia J, et al., 2016, Verteporfin, a suppressor https://doi.org/10.18632/oncotarget.21913

Volume 2 Issue 2 (2023) 11 https://doi.org/10.36922/gpd.0658